These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38675419)

  • 1. Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?
    Gil-Sánchez A; Gonzalo H; Canudes M; Nogueras L; González-Mingot C; Valcheva P; Torres P; Serrano JC; Peralta S; Solana MJ; Brieva L
    Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis.
    Lopez-Soley E; Solana E; Martínez-Heras E; Andorra M; Radua J; Prats-Uribe A; Montejo C; Sola-Valls N; Sepulveda M; Pulido-Valdeolivas I; Blanco Y; Martinez-Lapiscina EH; Saiz A; Llufriu S
    Front Neurol; 2020; 11():581700. PubMed ID: 33193039
    [No Abstract]   [Full Text] [Related]  

  • 3. A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort.
    van Dam M; de Jong BA; Willemse EAJ; Nauta IM; Huiskamp M; Klein M; Moraal B; de Geus-Driessen S; Geurts JJG; Uitdehaag BMJ; Teunissen CE; Hulst HE
    J Neurol; 2023 Aug; 270(8):3851-3861. PubMed ID: 37101095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment in people with multiple sclerosis: Perception vs. performance - factors that drive perception of impairment differ for patients and clinicians.
    Jackson DA; Nicholson R; Bergmann C; Wilken J; Kaczmarek O; Bumstead B; Buhse M; Zarif M; Penner IK; Hancock LM; Golan D; Doniger GM; Bogaardt H; Barrera M; Covey TJ; Gudesblatt M
    Mult Scler Relat Disord; 2023 Jan; 69():104410. PubMed ID: 36399966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab.
    Karampampa K; Gyllensten H; Friberg E; Murley C; Kavaliunas A; Hillert J; Olsson T; Alexanderson K
    BMJ Open; 2023 May; 13(5):e067516. PubMed ID: 37192793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does multilingualism act as a protective factor (cognitive reserve) against cognitive impairment in multiple sclerosis?: A retrospective cohort study.
    Morrow SA; Balusha AAK; Rosehart H; Casserly C; Racosta JM
    Mult Scler Relat Disord; 2023 Dec; 80():105060. PubMed ID: 37866025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting.
    Lanzillo R; Sparaco M; Lavorgna L; Carmisciano L; Signoriello E; Signori A; Costabile T; Maniscalco GT; Saccà F; Cepparulo S; Russo CV; Bisecco A; Frattaruolo N; Strianese A; Lus G; Brescia Morra V; Bonavita S
    Neurol Sci; 2020 Nov; 41(11):3235-3241. PubMed ID: 32388646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief international cognitive assessment for multiple sclerosis (BICAMS): A danish validation study of sensitivity in early stages of MS.
    Marstrand L; Østerberg O; Walsted T; Skov AC; Schreiber KI; Sellebjerg F
    Mult Scler Relat Disord; 2020 Jan; 37():101458. PubMed ID: 31683230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
    Weinstein A; Schwid SR; Schiffer RB; McDermott MP; Giang DW; Goodman AD
    Arch Neurol; 1999 Mar; 56(3):319-24. PubMed ID: 10190822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is computerized screening for processing speed impairment sufficient for identifying MS-related cognitive impairment in a clinical setting?
    Galioto R; Macaron G; Lace JW; Ontaneda D; Rao SM
    Mult Scler Relat Disord; 2021 Sep; 54():103106. PubMed ID: 34217998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spectral slope as a marker of excitation/inhibition ratio and cognitive functioning in multiple sclerosis.
    Akbarian F; Rossi C; Costers L; D'hooghe MB; D'haeseleer M; Nagels G; Van Schependom J
    Hum Brain Mapp; 2023 Dec; 44(17):5784-5794. PubMed ID: 37672569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and physical performance in multiple sclerosis patients with and without cognitive impairment: a cross-sectional study.
    Ozkul C; Guclu-Gunduz A; Eldemir K; Apaydin Y; Yazici G; Irkec C
    Int J Rehabil Res; 2020 Dec; 43(4):316-323. PubMed ID: 32804701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphosyntactic Abilities and Cognitive Performance in Multiple Sclerosis.
    Grigoriadis P; Bakirtzis C; Nteli E; Boziki MK; Kotoumpa M; Theotokis P; Kesidou E; Stavrakaki S
    Brain Sci; 2024 Feb; 14(3):. PubMed ID: 38539625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Blood Concentration of Metallic Nanoparticles Is Related to Cognitive Performance in People with Multiple Sclerosis: An Exploratory Analysis.
    de Oliveira M; Santinelli FB; Lisboa-Filho PN; Barbieri FA
    Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disability outcomes in early-stage African American and White people with multiple sclerosis.
    Petracca M; Palladino R; Droby A; Kurz D; Graziano N; Wang K; Riley C; Howard J; Klineova S; Lublin F; Inglese M
    Mult Scler Relat Disord; 2023 Jan; 69():104413. PubMed ID: 36399964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and patterns of subclinical motor and cognitive impairments in non-disabled individuals with early multiple sclerosis: A multicenter cross-sectional study.
    Cattaneo D; Gervasoni E; Anastasi D; Di Giovanni R; Brichetto G; Carpinella I; Cavalla P; Confalonieri P; Groppo E; Prosperini L; Tacchino A; Rovaris M; Solaro C
    Ann Phys Rehabil Med; 2022 Jan; 65(1):101491. PubMed ID: 33454397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis.
    Wenger AL; Barakovic M; Bosticardo S; Schaedelin S; Daducci A; Schiavi S; Weigel M; Rahmanzadeh R; Lu PJ; Cagol A; Kappos L; Kuhle J; Calabrese P; Granziera C
    Front Neurosci; 2023; 17():1007580. PubMed ID: 36824214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood lactate concentrations during rest and exercise in people with Multiple Sclerosis: A systematic review and meta-analysis.
    Cerexhe L; Easton C; Macdonald E; Renfrew L; Sculthorpe N
    Mult Scler Relat Disord; 2022 Jan; 57():103454. PubMed ID: 34915317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in metacognition between multiple sclerosis phenotypes: cognitive impairment and fatigue are key factors.
    Coll-Martinez C; Salavedra-Pont J; Buxó M; Quintana E; Quiroga-Varela A; Robles-Cedeño R; Puig M; Álvarez-Bravo G; Ramió-Torrentà L; Gich J
    Front Psychol; 2023; 14():1163112. PubMed ID: 37680235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.